



## **CHINA HEALTH GROUP INC.**

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 08225)

### **INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2024**

#### **CHARACTERISTIC OF THE GEM OF STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)**

**GEM has been positioned as a market designed to accommodate small and mid-size companies to which a high investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risk of investing in such companies and should make the decision to invest after due and careful consideration.**

**Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.**

The Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the “Directors”) of China Health Group Inc. (the “Company”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the “GEM Listing Rules”) of the Stock Exchange for the purpose of giving information with regard to the Company and its subsidiaries (together, the “Group”). The Directors, having made all reasonable enquires, confirm that, to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this report misleading.



## **CHINA HEALTH GROUP INC.**

### **中國醫療集團有限公司**

(Carrying on business in Hong Kong as “萬全醫療集團”)

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 08225)

#### **FINANCIAL HIGHLIGHTS**

1. For the six months ended 30 June 2024, the Group recorded an operating income of approximately RMB18,293,013, operating income increased by approximately 21.75% from RMB15,024,938 for the same period in 2023.
2. For the six months ended 30 June 2024, the Group recorded a profit before tax of approximately RMB8,651,000, compared with the profit before tax of RMB6,854,000 for the same period in 2023, an increase of approximately 26.22%.
3. For the six months ended 30 June 2024, the Group recorded a gross profit of RMB11,982,000, representing a gross margin of approximately 65.5%; gross profit for the same period in 2023 was RMB9,686,000 and gross margin was approximately 65%.
4. The Board does not recommend the payment of any interim dividends for the Period.

#### **INTERIM RESULTS (UNAUDITED)**

The board of Directors (the “Board”) is here to present the condensed unaudited consolidated interim results of the Group for the six months ended 30 June 2024, together with the comparative condensed unaudited consolidated figures for the corresponding period in 2023.

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER  
COMPREHENSIVE INCOME (UNAUDITED)**

For the six months ended 30 June 2024

	<i>Unaudited</i>	
	<i>Six months ended 30 June</i>	
	<b>2024</b>	<b>2023</b>
	<b>RMB'000</b>	<b>RMB'000</b>
<b>Turnover</b>	18,293	15,025
<b>Cost of sales</b>	-6,311	-5,339
<b>Staff cost</b>	-2,280	-1,826
<b>Other income</b>	4	18
<b>Administrative expenses</b>	-1,040	-1,052
<b>Profit from operations</b>	<hr/> 8,666	<hr/> 6,826
<b>Finance costs</b>	-15	28
<b>Profit before taxation</b>	<hr/> 8,651	<hr/> 6,854
<b>Income tax</b>	-1,298	-1,028
<b>Profit for the period</b>	<hr/> 7,353	<hr/> 5,826
<b>Attributable to:</b>		
<b>owners of the Company</b>		
<b>Profit for the period</b>	<hr/> 7,353	<hr/> 5,826
<b>Earnings per share (cents)</b>		
<b>- basic</b>	0.74	0.6
<b>- diluted</b>	0.74	0.6

## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 June 2024

	<b>Unaudited</b> <b>30-Jun-24</b> <b>RMB'000</b>	<b>Audited</b> <b>31-Dec-23</b> <b>RMB'000</b>
<b>Non-current assets</b>		
Property, plant and equipment	8,530	7,169
	<hr/> 8,530	<hr/> 7,169
<b>Current assets</b>		
Contract costs	17,287	20,393
Trade and bills receivables	75,258	65,399
Trade deposit paid	0	0
Prepayments and other receivables	19,130	19,085
Investments at fair value through profit or loss	1,663	3,163
Cash and cash equivalents	6,858	4,140
	<hr/> 120,196	<hr/> 112,180
<b>Current liabilities</b>		
Trade payables, other payables and accrued charges	<hr/> 12,990	<hr/> 12,073
Contract liabilities	1,014	1,014
Tax payable	23,186	22,079
Bank borrowings	<hr/> -	<hr/> -
	37,190	35,166
<b>Net current assets</b>	83,006	77,014
<b>Total assets less current liabilities</b>	91,536	84,183
<b>Net assets</b>	<hr/> 91,536	<hr/> 84,183
<b>Capital and reserves</b>		
Share capital	88,906	88,906
Reserves	3,266	-4,087
Non-controlling interests	-636	-636
<b>Total equity</b>	<hr/> 91,536	<hr/> 84,183

## CONDENSED CONSOLIDATED CASH FLOW STATEMENT (UNAUDITED)

For the six months ended 30 June 2024

	Unaudited	
	Six months ended 30 June	
	2024	2023
	RMB'000	RMB'000
Net cash (used in)/generated from operating activities	2,883	1,164
Net cash used in investing activities	(165)	(490)
Net cash used in financing activities	<u>0</u>	<u>(200)</u>
Net decrease in cash and cash equivalents	2,718	474
Cash and cash equivalents at beginning of the period	<u>4,140</u>	<u>4,060</u>
Cash and cash equivalents at end of the period	<u><b>6,858</b></u>	<u><b>4,534</b></u>

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the six months ended 30 June 2024

	Share capital RMB'000	Share premium RMB'000	Share Based payment reserve RMB'000	Special reserve RMB'000	Capital reserve RMB'000	Statutory reserve RMB'000	Statutory enterprise expansion fund RMB'000	Retained (losses)/ earnings RMB'000	Total equity RMB'000
At 1 January 2023	88,906	1,402	4,970	6,039	6,231	23,661	6,986	3,688	141,883
Profit for the period	-	-	-	-	-	-	-	5,826	5,826
Equity settled Share- based transactions									
At 30 June 2023	<u>88,906</u>	<u>1,402</u>	<u>4,970</u>	<u>6,039</u>	<u>6,231</u>	<u>23,661</u>	<u>6,986</u>	<u>9,514</u>	<u>147,709</u>
At 1 January 2024	88,906	1,402	4,923	6,039	6,231	23,661	6,986	(53,965)	84,183
Profit for the period	-	-	-	-	-	-	-	7,353	7,353
At 30 June 2024	<u>88,906</u>	<u>1,402</u>	<u>4,923</u>	<u>6,039</u>	<u>6,231</u>	<u>23,661</u>	<u>6,986</u>	<u>(46,612)</u>	<u>91,536</u>

## **NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

For the six months ended 30 June 2024

### **1. Corporate information**

The Company was incorporated in the Cayman Islands on 21 May 2002 as an exempted company with limited liability under the Companies Law of the Cayman Islands. The address of its registered office is P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1- 1205, Cayman Islands and its principal place of business is Building 17, Jianwai SOHO, Chaoyang District, Beijing, the People's Republic of China (the "PRC"). The Company has had its shares listed on The Growth Enterprise Market of the Stock Exchange of Hong Kong Limited since 10 July 2003.

The Company is an investment holding company. The principal activities of its subsidiaries are to provide fully integrated pharmaceutical services including clinical research services, post marketing surveillance, real-world study, medical science events, medical marketing and product promotion service, and other medical services. The Company is focusing on building itself into a group corporation providing comprehensive terminal medical service under international architecture.

### **2. Adoption of new and revised international financial reporting standards**

In the current Period, the Group has adopted all the new and revised Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") that are relevant to its operations and effective for its accounting year beginning on 1 January 2024. HKFRSs comprise Hong Kong Financial Reporting Standards; Hong Kong Accounting Standards ("HKAS"); and Interpretations. The adoption of these new and revised HKFRSs did not result in significant changes to the Group's accounting policies, presentation of the Group's financial statements and amounts reported for the current Period and prior periods.

The Group has not applied the new HKFRSs that have been issued but are not yet effective. The Group has already commenced an assessment of the impact of these new HKFRSs but is not yet in a position to state whether these new HKFRSs would have a material impact on its results of operations and financial position.

### **3. Accounting policies and basis of preparation**

These unaudited condensed consolidated financial statements have been prepared in accordance with all applicable HKFRSs issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong and the applicable disclosure provisions of the Rules Governing the Listing of Securities on The GEM of the Stock Exchange (the "GEM Listing Rules") and by the Hong Kong Companies Ordinance.

The accounting policies adopted in the preparation of these unaudited condensed consolidated financial

statements are consistent with those followed in the preparation of the Group’s audited consolidated financial statements for the year ended 31 December 2023 except for the changes in accounting policies, if required, in adopting new or revised HKFRSs and interpretations that are first effective for accounting periods beginning on or after 1 January 2024.

These unaudited condensed consolidated financial statements are presented in Renminbi (“RMB”) and it is also the functional currency of the Company.

#### 4. Revenue and segment information

The Company is principally engaged in providing research, development, medical science events and clinical registry. Breakdown of the revenue from all services is as follows:

	<b>Unaudited Six months ended 30 June</b>	
	<b>2024 RMB’000</b>	<b>2023 RMB’000</b>
Provision of post marketing surveillance, real-world study, medical science events, and medical marketing (PMS)	18,293	15,025
Total:	18,293	15,025

The turnover for the Period increased 21.75% compared with the corresponding period of 2023. Moreover, turnover of PMS for the six months ended 30 June 2024 increased 21.75% compared with the corresponding period of 2023. During the Period, the turnover of related parties was RMB5,434,000, accounting for 29.7% of the total turnover.

#### 5. Administrative expenses

	<b>Unaudited Six months ended 30 June</b>	
	2024 RMB’000	2023 RMB’000
Administrative expenses	(1,040)	(1,052)

Administrative expenses decreased about 1.14% compared with the corresponding period of 2023.



## **6. Earnings per share**

Basic earnings per share is calculated by dividing the unaudited net profit approximately RMB7,353,000元 (2023: RMB5,826,000) attributable to owners of the Company by the weighted average number of 995,351,660 ordinary shares of the Company for the Period (2023:995,351,660 Shares).

The calculation of the diluted earnings per share for the Interim is same as basic earnings per share which based on unaudited net profit attributable to owners of the Company. The weighted average number of ordinary shares of 995,351,660, being the weighted average number of ordinary shares of 995,351,660 in issue during the Period used in the basic earnings per share calculation plus the weighted average number of ordinary shares of 995,351,660 assumed to have been issued at no consideration on the deemed exercise of the share options outstanding at the end of the reporting Period. (2023: 995,351,660 Shares).

## **7. Income tax**

No Hong Kong profit tax has been provided for, as the Group had no estimated assessable profits in Hong Kong for the Period (the corresponding period: Nil).

“PRC” Enterprise Income Tax has been calculated on the estimated assessable profit for the Period according to the relevant laws and regulations. The applicable income tax rate is ranging from 9% to 25% as at 30 June 2023 (the corresponding period: 9%-25%). During the Period, some subsidiaries of the Company are eligible for tax incentives due to their location and industry. These subsidiaries are subject to a preferential tax rate of 15%. Taxation of other overseas subsidiaries are charged at the appropriate current rates of taxation ruling in the relevant countries.

## **8. Dividends**

The Board does not recommend the payment of any dividend for the Period (2023:Nil).

## 9. Trade and bills receivables

An aged analysis of the trade and bills receivables at the end of the reporting period, based on the invoice date and net of allowances, is as follows:

	Unaudited 30 June 2024	Audited 31 December 2023
	RMB'000	RMB'000
Within 180 days	6,137	11,956
181 to 360days	24,568	10,769
361 to 540days	6,769	711
541 to 720days	711	1,031
721 to 900days	0	7,765
901 to 1080days	5,750	11,689
over 1080 days	31,323	21,478
	<hr/>	<hr/>
	75,258	65,399
	<hr/>	<hr/>

## 10. Trade payables, other payables and accrued charges

As of the end of the reporting period, the ageing analysis of trade payables, based on the invoice date, is as follows:

	Unaudited 30 June 2024 RMB'000	Audited 31 December 2023 RMB'000
Within 30 days	35	69
31 to 90 days	69	17
91 to 365 days	934	0
Over 365 days	11,952	11,987
	<hr/> 12,990 <hr/>	<hr/> 12,073 <hr/>

## 11. Equity settled Share-based transactions

The Company has a share option scheme which was adopted on 20 June 2003 whereby the directors of the Company are authorized, at their discretion, to invite employees of the Group, including directors of any company in the Group, to take up options at predetermined considerations to subscribe for shares of the Company.

## 12. Financial Assistance

The financial assistance provided by the Group as of December 31, 2023 is:

The trade receivables from affiliated parties amount to approximately RMB 57,999,000. The credit period for collection is extended to the next two years.

As mentioned on page 63 (i) of the 2023 annual report, the trade receivables of the affiliated companies controlled by Mr. Guo Xia, a director and the ultimate controlling shareholder of the Group (Company), amount to approximately RMB 57,999,000. The affiliated companies confirm that the repayment shall be made in the next two years, that is, to be completed before December 31, 2025. Such trade receivables, like other trade accounts receivables, are non-mortgaged, unsecured, interest-free with general commercial terms, and the transactions have no impact on the company's profits.

The deferred recipients are referred to Wante Hainan Co. and Wanquan Xiamen Co., which are mentioned in the continuous closing trade letters on June 24, 2022. If the payment is delayed due to the irresistible reason of the epidemic, the repayment will be handled in installments. This transaction is a one-time transaction.

For the deferred receivables of the year, the Group required the other parties to sign the commitment letter of repayment, and received the confirmation letter on the repayment from the affiliated parties on March 7, 2023 and March 21, 2024 respectively. This matter constitutes the financial assistance.

The Group's consolidated financial statement as of 31 December 2023 is prepared in accordance with the Group's accounting policies and has been adjusted to comply with the Group's main accounting policies and reclassified by the main classification of the financial statement.

The Group has taken the following measures on June 19, 2024 to prevent similar situations from occurring:

- 1.Improve internal supervision: to ensure the implementation of continuous monitoring activities through the daily monitoring system.
- 2.Strengthen internal audit: the internal audit institutions or institutions that perform internal audit functions are independent of the audited department, and to supervise the effectiveness of the control system, and timely report the defects.
- 3.Information technology support: to use information technology system to support internal control process management, realize paperless file system and automation of process execution, in order to improve efficiency.
- 4.Approval authority and procedures: to clearly define the approval authority and procedures for providing external financial assistance, ensure that all matters relating to financial assistance are reviewed by the board of directors, and submitted to the board of directors or general meeting of shareholders for review when necessary.
- 5.Information disclosure: to fully disclose matters regarding providing financial assistance, including the basic situation of the assisted objects, risk prevention measures, opinions of the board of directors, etc.
- 6.Explicit responsibilities and division of workload: to clearly define the responsibilities and division of workload of relevant departments such as the finance department, the secretary of the board of directors, and the internal audit department in financial assistance matters.
- 7.Risk assessment and control: to conduct risk assessment on the parties that receiving funds, including their asset quality, business situation, solvency, etc., and take corresponding risk control measures.
- 8.System construction: to improve the "Financial Assistance Management System" and to ensure that the activities of providing external financial assistance are in compliance with laws and regulations and to prevent financial risks.
- 9.Training and communications: to provide training to relevant employees to make them understand the financial assistance policies and procedures as well as the consequences of violations, and to maintain effective communications between departments to ensure timely transmission of information.

## **MANAGEMENT DISCUSSION AND ANALYSIS**

### **BUSSINESS REVIEW**

Since listing, China Health Group has provided full chain services from drug research and development to marketing, focusing on drug research and development (PDS), registration, and premarket clinical research in the early stage. In the later stage, it gradually focused on post-marketing clinical research, especially real-world clinical research (CHG RWS); Among the post-market clinical research-driven marketing Outreach Services (CRSO) and Specialty Medical Services (CHG MyD), bioequivalence studies, as a specialized service, are also included in CHGRWS.

The Group's business vision is to become a leader in real-world clinical research services, focusing on the five major areas of mental illness, neurological disease, allergic disease, rare disease and viral infectious disease, through the construction of RWD(Real world data) RWS(Real world clinical research) AI(artificial intelligence) three core competencies.

We offer three major business services for the life sciences,

- 1 "Research specialty" of precision digital medicine
- 2.RWS drug clinical research replaces RCT
- 3 Replace CSO with "research product promotion CRSO service.

Since the first half of 2024, the pharmaceutical industry has experienced a recovery period from the epidemic to the exciting period of gradually returning to business normal, and the group's business has also steadily developed, especially the CRSO business after listing, with strong demand. In terms of scientific research services, the group's "RWS Wanquan Center" is a surefire way to re-screen and group existing drugs through real clinical research with big data to find the best treatment. The Group established a biological sample testing laboratory, equipped with Waters UPLC-MS/MS.Xevo TQS, which was officially opened to the public. The laboratory mainly serves clinical research, especially clinical research experiments of antiviral drugs.

## **FINANCIAL REVIEW**

The Group achieved a turnover of RMB18,293,013 during the Period, representing an increase of approximately 21.75% from RMB15,024,938 as compared with that of the corresponding period of 2023.

The condensed consolidated turnover included approximately RMB18,293,013 derived from the post marketing surveillance, real-world clinical research, medical science and medical market services (PMS), amounted to 100% of the total turnover, which was representing an increase of approximately 21.75% from RMB15,024,938 as compared with that of the corresponding period of 2023.

The Group recorded a profit before taxation of approximately RMB8,651,000 for the Period, representing an increase of 26.22% from RMB6,854,000 as compared with that of the corresponding period of 2023. Profit for the Period was approximately RMB7,353,000, and in the corresponding period of last year were approximately RMB5,826,000.

Total condensed consolidated administrative expenses and staff costs were approximately RMB3,320,000 for the Period and the corresponding period of last year was approximately RMB2,878,000.

## **LIQUIDITY, FINANCIAL RESOURCES AND GEARING RATIO**

As at 30 June 2024, the Group's net current assets and its net assets were approximately RMB83,006,000 (31 December 2023: approximately RMB77,014,000) and approximately RMB91,536,000 (31 December 2023: approximately RMB84,183,000) respectively.

During the Period, the Group financed its operations with its own working capital. The Group did not have any bank borrowings (31 December 2023: nil) and hence the gearing ratio (31 December 2023: not applicable) was not applicable as at 30 June 2024.

Meanwhile, considering the working capital and long term fund demand for future development, the Group will consider to raise further funds through bank loans, issuance of new shares, convertible notes, and issuance of new debts, etc.

## PROSPECTS

At present, as the global economic goes down, the financing of the new drug sector goes cold and the domestic innovative drug industry chain has entered the bubble clearing stage, there is a clear head-effect and the strong constant strong situation in the medical service industry (CXO). We return to the industry as a service company with the goal to achieve the curve overtaking, the main strategy is as follows:

Strategy 1: Make full use of the advantages of the Group in Hainan (Wanquan Medical Health (Hainan) Co., LTD.) and the geographical advantages of Hainan's national free trade zone in 2025 to obtain new customers.

There are "four licenses" of Hainan Medical Tourism Pilot Zone , including franchised medical treatment, franchised research, franchised operation and franchised international exchange, and it leads in the country to carry out international cutting-edge clinical real-world data application pilot. With the help of clinical real-world data assisted clinical evaluation approved for registration and listing in China, it can greatly shorten the time for foreign innovative pharmaceutical devices to enter the domestic market, and it has become the company's biggest advantage in obtaining customers.

Strategy 2: Make full use of the advantages of Hainan's first national real world research platform, attract overseas customers to enter China quickly, and provide customers with a package of services including follow-up registration, clinical research, and post-market promotion.

In September 2019, the State Food and Drug Administration and the Hainan Provincial Government jointly issued the Implementation Plan for the Clinical Real-world Data Application Pilot Work in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, carried out the clinical real-world data application pilot work, and explored the conversion of clinical data of licensed pharmaceutical devices not registered in China and approved for use in the Lecheng Pilot Zone into real-world evidence for registration and approval in China.

By the end of 2022, the first cases of imported licensed pharmaceutical equipment varieties in the Lecheng Pilot Zone reached 290, and the total number of users was nearly 18,000. More than 20 licensed pharmaceutical device products have been included in the clinical real-world data application pilot, of which 9 pilot products have obtained domestic registration by using real-world evidence to assist clinical evaluation.

Based on this, among the current customers of the company, a number of rare disease drug companies hope to enter China through Hainan and our services.

Strategy 3 :focuses on TCM clinical research services to become the industry leader

In recent years, the Chinese medicine policy has continued to improve, encouraging the inheritance and innovation of Chinese medicine, but the research and development of Chinese medicine involves many components, the pharmacological mechanism is complex, the current clinical effectiveness evaluation is insufficient, and the development of Chinese medicine CRO industry is still relatively lagging and limited. On February 28, The General Office of the State Council issued the Implementation Plan for the Major Project for the revitalization and development of Traditional Chinese Medicine, pointing out that inheriting and innovating traditional Chinese medicine is an important part of the cause of socialism with Chinese characteristics in the new era and a major

event for the great rejuvenation of the Chinese nation. In early February this year, the Food and Drug Administration just issued the "Special Regulations on the Registration and Management of Chinese Medicine", which continued and innovated the reform of drug evaluation and approval, and improved the evaluation and approval system of Chinese medicine in line with the characteristics of traditional Chinese medicine.

The "Special Provisions" specifically states the requirements of "drug name and description", and specifically mentions that any item in the "contraindications", "adverse reactions", and "precautions" of the instructions of traditional Chinese medicine is still "unclear" at the time of applying for drug re-registration, and it will not be re-registered. Due to historical reasons, more than 70% of Chinese traditional medicine instructions, at least one column of [contraindications], [adverse reactions], [precautions] is not clear. According to Yaozhi data, the total number of Chinese traditional medicine approvals is 57,526, that is, at least 40,000 Chinese traditional medicine approvals need to be considered for re-registration. This market value is more than one trillion yuan.

In the past 20 years, China Health Group has completed hundreds of TCM clinical projects, and we believe that we can take advantage of this east wind with our rich experience and customer resources.

Strategy 4: Medical-driven marketing, creating a CRSO paradigm of 100 clinical trials and bringing 10 billion market

Recently, the Central Commission for Discipline Inspection and the State Supervision Commission and the Central Organization Department, the Central United Front Work Department, the Central Political and Legal Commission, the Supreme People's Court, and the Supreme People's Procuratorate jointly issued the "Opinions on Further promoting bribery and bribery investigation", a number of ministries and commissions, jointly occurred, in the harshest terms, pushing the compliance operation of the medical industry to a new height. The opinions pointed out that adhering to no restricted areas, full coverage, zero tolerance, adhering to heavy containment, strong pressure, long deterrence, and adhering to bribery and bribery together, so that the integration of not daring to corrupt, not able to corrupt, and not wanting to corrupt has more institutional results and greater governance results. At the same time, the Health and Health Commission issued the "Nine Guidelines for Clean Employment of Medical Institution Staff".

With the tightening of various policies and more medical behavior constraints, drug production enterprise personnel and agents are more and more difficult to contact the clinicians, gold tax phase 4 financial penetration supervision makes cost extraction more and more difficult. The old sales model has begun to accelerate to expire. Therefore, it has become inevitable for marketing to take medicine as the guide and comply with compliance requirements to enhance product visibility and corporate reputation in the process of clinical research, and to use clinical research to further explore product characteristics and convert them into patient benefits. Therefore, the CRSO model of China Health Group will certainly attract a large number of pharmaceutical enterprises and bring explosive business growth to the group.



## **DIVIDENDS**

The Board does not recommend the payment of any interim dividends for the Period (2023: Nil).

## **SIGNIFICANT INVESTMENT**

Saved as disclosed in this report, there was no significant investment during the Period (2023: Nil).

## **SIGNIFICANT COMMITMENTS**

As at 30 June 2024, the Group did not have any significant capital commitments (31 December 2023: Nil).

## **MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES AND ASSOCIATES**

During the Period, the Group did not carry out any material acquisitions and disposals in respect of subsidiaries and associates (2023: Nil).

## **CHARGE ON ASSETS**

As at 30 June 2024, no banking facilities were available to the Group (31 December 2023: Nil).

As at 30 June 2024, the Group did not charge on any of its assets (31 December 2023: Nil).

## **CONTINGENT LIABILITIES**

As at 30 June 2024, the Group did not have any significant contingent liabilities (31 December 2023: Nil).

## **CAPITAL STRUCTURE**

During the Period, there had been no changes in the Company's capital including ordinary shares and capital reserve structure. As at 30 June 2024, the issued shares amounted to 995,351,660.

## **FUTURE PLANS FOR SIGNIFICANT INVESTMENTS OR CAPITAL ASSETS**

Other than those disclosed in the Company's public announcements, the Group does not have any other plans for significant investments or capital assets.

## **FOREIGN EXCHANGE EXPOSURE**

During the Period, the Group's transactions were substantially denominated in Renminbi ("RMB"). The Group closely monitors its foreign currency risk from time to time and will use appropriate hedging when necessary.

## **TREASURY POLICIES**

The Directors will continue to follow a prudent policy in managing the Group's cash and maintaining a strong and healthy liquidity to ensure that the Group is well placed to take advantage of future growth opportunities.

## **EVENT DURING THE PERIOD**

On 11 May 2020, the Company and Mr. GUO Xia, including the companies controlled by Mr. GUO Xia including but not limited to Wante Pharmaceutical (Hainan) Co., Ltd., Wanquan Wante Pharmaceutical (Xiamen) Co., Ltd. and Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. (the "Excluded Group"), have entered into the new framework service agreement (the "New Framework Service Agreement"). According to the New Framework Service Agreement, the Company will provide post-marketing clinical research, medical research and medical market services to the Excluded Group from the date of the New Framework Service Agreement to 31 December 2024. The annual caps for the New Framework Service Agreement for the years ending 31 December 2022, 2023 and 2024 are RMB50,000,000, RMB60,000,000 and RMB72,000,000 respectively.

For details, please refer to the Company's announcements dated 11 May 2022, 1 June 2022, 12 July 2022 and 13 July 2022 and the Company's circular dated 24 June 2022.

## **EVENT AFTER THE PERIOD**

There is no material subsequent event undertaken by the Company or by the Group after 30 June 2024 and up to the date of this report.

## **HUMAN RESOURCES**

The Group's remuneration policy is basically determined by the performance of individual employees. In addition to salaries and bonuses, The Group also provided various other benefits to its employees. Employee benefits included medical and pension contributions and share options schemes.

The Group monitored closely the remuneration and fringe benefits of the employees and rewarded employees in accordance with the Group's business performance. In addition, training and development opportunities for the employees were also provided by the Group.

## **EMPLOYEE AND REMUNERATION POLICY**

The Group employed 41 employees as at 30 June 2024. During the Period, staff cost, including directors' remuneration, is approximately RMB2,280,000 (2023: approximately RMB1,826,000). The Group remunerates its employees based on their performance, and the prevailing market price.

The Company adopted the share option scheme where share options to subscribe for shares of the Company have been granted to the eligible participants of the Group.

The movements in the share options granted under the share option scheme of the Company during the Period are set out in the section headed "Share Option Scheme" in this report.

## **OTHER INFORMATION**

### **PURCHASE, SALE OR REDEMPTION OF SECURITIES**

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed shares (including treasury shares) for the Period.

## COMPETING INTERESTS

None of the Directors or the substantial shareholders of the Company or their respective close associates (as defined in the GEM Listing Rules) has interests in any business apart from the Group's businesses which competes or is likely to compete, either directly or indirectly, with the businesses of the Group during the Period and up to the date of this report.

## DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ANY ASSOCIATED CORPORATIONS

As at 30 June 2024, the interests and short positions of the Directors and chief executives in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO"), which are required (a) to notify the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have taken under such provision of the SFO); or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules were as follows:

### Long positions in shares and underlying shares of the Company

Name of Directors	Capacity/ Nature of interests	Number of ordinary shares held/ interested	Number of underlying shares held/ interested pursuant to share options	Total number of shares	Approximate percentage of the total number of issued shares of the Company
GUO Xia	Beneficial Owner	114,701,941	18,150,000 (note 2)	132,851,941	13.35%
	Interest in a controlled corporation	590,716,637 (note 1)	-	590,716,637	59.35%
SONG Xuemei	Beneficial owner	6,500	410,000 (note 2)	416,500	0.04%
ZHANG Li	Beneficial owner	960,000	-	960,000	0.96%
NI Binhui	Beneficial owner	100,000	100,000 (note 2)	200,000	0.02%
QIU Rui (resigned on 5 February 2024)	Beneficial owner	-	120,000 (note 2)	120,000	0.01%
ZHEN Ling (resigned on 21 September 2023)	Beneficial owner	-	100,000 (note 2)	100,000	0.01%

Notes:

1. According to information available to the Company, 349,368,873 shares were beneficially owned by Winsland Agents Limited, a company wholly owned by Mr. GUO Xia. 91,915,181 shares were beneficially owned by Bright Excel Assets Limited, a company wholly owned by Venturepharm Holdings Inc., approximately 49.00% of its shares were held Winsland Agents Limited and approximately 47.63% were held by Mr. GUO Xia. 149,432,583 shares were beneficially owned by Venturepharm Holdings Inc. As such, Mr. GUO Xia is deemed to be interested in the above companies under the SFO.
2. These share options were granted by the Company under the Share Option Scheme. For details, please refer to the paragraph headed “Share Option Scheme”.

Saved as disclosed above, as at 30 June 2024, none of the Directors and chief executives of the Company had any other interests or short positions in any shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which (a) were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (c) were required, pursuant to the required standard of dealings by Directors as referred to in Rule 5.46 to Rule 5.67 of the GEM Listing Rules, to be notified to the Company and the Stock Exchange.

#### **SUBSTANTIAL SHAREHOLDERS AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY**

So far as the Directors are aware, as at 30 June 2024, other than the Directors or chief executives of the Company whose interests or short positions are disclosed under the paragraph headed “Directors’ and Chief Executives’ Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company and any Associated Corporations” above, the following person has an interest or short position in the Shares or underlying Shares which has to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO and as recorded in the register required to be kept under Section 336 of the SFO, and who were expected, directly or indirectly, to be interested in 5% or more of the Shares are listed as follows:

**Long Positions in the Shares:**

<b>Name of Shareholders</b>	<b>Capacity/ Nature of interests</b>	<b>Number of ordinary shares held/ interested</b>	<b>Approximate percentage of the total number of issued shares of the Company</b>
Winsland Agents Limited	Beneficial Owner	349,368,873	35.10%
	Interest in a controlled corporation	241,347,764 (note)	24.25%
Bright Excel Assets Limited	Beneficial owner	91,915,181	9.23%
Venturepharm Holdings Inc.	Beneficial owner	149,432,583	15.01%
	Interest in a controlled corporation	91,915,181 (note)	9.23%

*Note: According to information available to the Company, 91,915,181 shares were beneficially owned by Bright Excel Assets Limited, a company wholly owned by Venturepharm Holdings Inc., approximately 49.00% of its shares were held Winsland Agents Limited and approximately 47.63% were held by Mr. GUO Xia. As such, Winsland Agents Limited and Venturepharm Holdings Inc. are deemed to be interested in the shares of the Company owned by Bright Excel Assets Limited under the SFO, and Winsland Agents Limited is deemed to be interested in the shares of the Company owned by Venturepharm Holdings Inc. under the SFO.*

Saved as disclosed above, as at 30 June 2024, the Directors were not aware of any other person (other than the Directors or chief executives as disclosed in the paragraph headed “Directors’ and Chief Executives’ Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company and any Associated Corporations” above) who had, or deemed to have, interests or short positions in the shares, underlying Shares which has to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO and as recorded in the register required to be kept under Section 336 of the SFO.

**DIRECTORS’ RIGHTS TO ACQUIRE SHARES OR DEBENTURES**

Apart from the details as disclosed under the headings “Directors’ and Chief Executives’ Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company or any Associated Corporation” above and “Share Option Scheme” below, at no time during the Period was the Company, its holding company, or any of its subsidiaries or associated corporations, a party to any arrangement that would enable the Directors and chief executives of the Company or their respective associates (as defined in the GEM Listing Rules) to have any right to subscribe for securities of the Company or any of its associated corporations as defined in the SFO or to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporate.

## **SHARE OPTION SCHEME**

On 30 June 2015, the Company passed an ordinary resolution at the annual general meeting to adopt a new share option scheme (the “Share Option Scheme”). The Share Option Scheme will remain in force for a period of 10 years commencing from the date of adoption of the Share Option Scheme from 30 June 2015 (the “Date of Adoption”) (that is from 30 June 2015 to 29 June 2025), after which period no further options will be granted but the provisions of the Share Option Scheme shall remain in full force and effect in all aspect. The major terms of the Share Option Scheme are summarised as follows:

### **Purpose of the Share Option Scheme**

- (a) The Share Option Scheme is a share incentive scheme and is established to recognize and acknowledge the contributions and potential contributions which the eligible participants have made or may make to the Group.
- (b) The Share Option Scheme will provide the Eligible Participants with an opportunity to have a personal stake in the Company with a view to motivating the Eligible Participants to utilize their performance and efficiency for the benefit of the Group and attracting and retaining or otherwise maintaining an on-going relationship with the Eligible Participants whose contributions are or will be beneficial to the long term growth of the Group.

### **The Eligible Participants**

The participants of the Share Option Scheme include (i) any director, employee (whether full time or part time employee), consultant or adviser of or contractor to the Group or any entity in which any member of the Group holds any interest (the “Invested Entity”); (ii) any discretionary trust whose discretionary objects include any director, employee (whether full time or part time employee), consultant or adviser of or contractor to the Group or any Invested Entity; and (iii) a company beneficially owned by any director, employee (whether full time or part time employee), consultant or adviser of or contractor to the Group or any Invested Entity, who, in the absolute discretion of the Board (the “Eligible Participants”), has contributed or may contribute to the Group.

### **The exercise price of a share option**

The exercise price of a share option under the Share Option Scheme will not be less than the highest of (i) the closing price of the Shares on the Stock Exchange as shown in the daily quotations sheet of the Stock Exchange on the offer date of the particular option, which must be a business day; (ii) the average of the closing prices of the Shares as shown in the daily quotations sheets of the Stock Exchange for the five business days immediately preceding the offer date of that particular option; and (iii) the nominal value of a share on the offer date of the particular option.

## **Maximum number of shares available for subscription under the Share Option Scheme**

### **(a) 30% limit**

The overall limit on the number of Shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the Share Option Scheme and any other share option schemes of the Company must not exceed 30% of the Shares in issue from time to time (the “Scheme Limit”).

### **(b) 10% limit**

In addition to the Scheme Limit, and subject to the following paragraph, the total number of Shares which may be issued upon exercise of all options to be granted under the Share Option Scheme and any other share option schemes of the Company must not in aggregate exceed 10% of the Shares in issue as at the date of approval of the Share Option Scheme (excluding any options which have lapsed in accordance with the terms of the Share Option Scheme or any other share option schemes of the Company) (the “Scheme Mandate Limit”).

The Company may, from time to time, refresh the Scheme Mandate Limit by obtaining the approval of the Shareholders at a general meeting. Once refreshed, the total number of securities which may be issued upon exercise of all options to be granted under the Share Option Scheme and all other share option schemes of the Company under the limit, as refreshed, must not exceed 10% of the Shares in issue as at the date of approval of the refreshed limit. Options previously granted under the Share Option Scheme and/or any other share option schemes, including without limitation any options which are outstanding, cancelled, lapsed or exercised, will not be counted for the purpose of calculating the refreshed Scheme Mandate Limit.

## **Maximum entitlement of each Eligible Participant**

Unless approved by the Shareholders, the total number of Shares issued and to be issued upon exercise of the options granted to each Eligible Participant (including both exercised and outstanding options) in any 12-month period must not exceed 1% of the Shares in issue. Where any further grant of options to an Eligible Participant would result in the Shares issued and to be issued upon exercise of all options granted and to be granted to such Eligible Participant (including exercised, cancelled and outstanding options) in the 12-month period up to and including the date of such further grant representing in aggregate over 1% of the relevant class of securities in issue, such further grant must be separately approved by the Shareholders in general meeting with such Eligible Participant and his associates abstaining from voting.

The total number of Shares available for issue under the Share Option Scheme, including the outstanding options, is 88,947,166 Shares, representing 8.94% of the total number of Shares in issue as at the date of this report.



**Performance target**

Unless otherwise determined by the Directors at their sole discretion, there is no performance target which must be satisfied or achieved before the options can be exercised.

**Minimum period for which an option must be held**

Unless otherwise determined by the Directors at their sole discretion, there is no requirement of a minimum period for which an option must be held before such an option can be exercised under the terms of the Share Option Scheme.

**Subscription price of Shares**

The Subscription Price must be at least the highest of: (a) the closing price of a Share as stated in the daily quotations sheet of the Stock Exchange on the date of grant which must be a Business Day; and (b) the average of the closing prices of the Shares as shown on the daily quotations sheets of the Stock Exchange for the five Business Days immediately preceding the date of grant; and (c) the nominal value of a Share.

**Amount payable upon acceptance of option**

HK\$1.00 is payable by each Eligible Participant to the Company on acceptance of an Offer of an option, which shall be paid within 21 days from the date of offer.

**Time of exercise of option**

An option shall be exercisable at any time during an option period to be notified by the Board to each grantee, provided that no option shall be exercisable later than ten years after its date of grant.

**Details of the share options movements during the Period under the Share Option Scheme are as follows:**

**Number of share options**

Name or category of grantees	Exercise Price (HK\$)	Date of grant	of	Exercisable period	Balance as at 1 January 2024	Granted during the Period	Exercised during the Period	Lapsed during the Period	Cancelled during the Period	Balance as at 30 June 2024
<b>Directors</b>										
GUO Xia	0.450	30 June 2015		Note 1	9,150,000	-	-	-	-	9,150,000
	0.504	24 March 2021		Note 2	9,000,000	-	-	-	-	9,000,000
SONG Xuemei	0.450	30 June 2015		Note 1	250,000	-	-	-	-	250,000
	0.504	24 March 2021		Note 2	160,000	-	-	-	-	160,000
NI Binhui	0.504	24 March 2021		Note 2	100,000	-	-	-	-	100,000
<b>Former Director</b>										
SU Yi	0.450	30 June 2021		Note 1	220,000	-	-	-	-	220,000
	0.504	24 March 2021		Note 2	100,000	-	-	-	-	100,000
QIU Rui	0.504	24 March 2021		Note 2	120,000	-	-	-	-	120,000
ZHEN Ling	0.504	24 March 2021		Note 2	100,000	-	-	-	-	100,000
<b>Employees of the Group</b>										
In aggregate	0.450	30 June 2015		Note 1	1,230,000	-	-	-	-	1,230,000
	0.504	24 March 2021		Note 2	5,070,000	-	-	120,000	-	4,950,000
Total					<b>25,500,000</b>	<b>-</b>	<b>-</b>	<b>120,000</b>	<b>-</b>	<b>25,380,000</b>

*Notes:*

1. *These options are under the Share Option Scheme. The options may not be exercised within one year from 30 June 2015. The option will vest (i) to the extent of a maximum of 40% of the offered shares on 30 June 2016; (ii) to the extent of a maximum of 70% of the offered shares on 30 June 2017; and (iii) to extent of all offered shares on 30 June 2018.*
2. *These options of the independent non-executive Directors shall be exercisable immediately from 24 March 2021, and the options of other persons may not be exercised within one year from 24 March 2021. The options will vest (i) to the extent of a maximum of 40% of the offered shares on 24 March 2022; (ii) to the extent of a maximum of 70% of the offered Shares on 24 March 2023; and (iii) to extent of all offered shares on 24 March 2024. The options must be exercised in whole board lots of 20,000 shares. The closing price of the*

*shares of the Company immediately before 24 March 2021, the date on which those options were granted, was HK\$0.500.*

Saved as disclosed above, no other share options were granted, exercised, cancelled or lapsed during the Period.

## **CORPORATE GOVERNANCE**

The Company's corporate governance practices are based on the principles and the code provisions as set out in the Corporate Governance Code (the "Code") as set out in part 2 of Appendix C1 to the GEM Listing Rules. The principles adopted by the Company emphasize a quality board, transparency and accountability to shareholders. In the opinion of the Board, the Company has complied with the Code for the Period, with the exception for the following deviation:

Under code provision C.2.1, the responsibilities between chairman and chief executive officer should be separated. However, the chief executive officer of the Company has not yet been appointed. Currently, the day-to-day management of the Company's business is handled by the executive Directors and senior management, who take the responsibility to run the Group's business and to implement the Group's strategy so as to achieve the overall commercial objectives of the Company.

Under code provision C.1.6, generally the independent non-executive directors should attend general meetings to gain and develop a balanced understanding of the views of shareholders. Under code provision F.2.2, the chairman of the board should invite the chairmen of the audit, remuneration, nomination and any other committees (as appropriate) to attend. In their absence, the chairman should invite another member of the committee or failing this their duly appointed delegate, to attend. These persons should be available to answer questions at the annual general meeting. An issuer's management should ensure the external auditor attend the annual general meeting to answer questions about the conduct of the audit, the preparation and content of the auditors' report, the accounting policies and auditor independence.

## **DIRECTORS' SECURITIES TRANSACTIONS**

The Company has adopted a code of conduct regarding securities transactions by Directors on terms no less exacting than the required standard of dealings set out in Rules 5.48 to 5.67 of the GEM Listing Rules. The Company also had made specific enquiry of all Directors and the Company was not aware of any non-compliance with the required standard of dealings and its code of conduct regarding securities transaction by Directors during the Period.

## **AUDIT COMMITTEE**

The Audit Committee was established with written terms of reference in compliance with the GEM Listing Rules. The primary duties of the Audit Committee are to review the Company's annual reports and accounts, half-yearly reports and internal control system of the Group and provide advice and comments to the Board. The Audit Committee comprises four independent non-executive Directors, namely Ms. LIU Na, Mr. WU Shuangsi, Dr. Ni Bin hui and Dr. GUO Tong. Ms. LIU Na is the chairman of the Audit Committee. The unaudited consolidated results of the Group for the Period had been reviewed by the Audit Committee, which was of the

opinion that the preparation of such results complied with the applicable accounting standards and requirements and that adequate disclosures have been made.

#### **SUFFICIENCY OF PUBLIC FLOAT**

Based on the information that is publicly available to the Company and within the knowledge of the Directors as at the date of this report the Company has maintained a sufficient public float.

**By Order of the Board**  
**China Health Group Inc.**  
GUO Xia  
Chairman

Hong Kong, 22 August 2024

*As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; two non-executive Directors, being Dr. ZHANG Li and Dr. WANG Dajun Denis; and four independent non-executive Directors, being Dr. NI Binhui, Dr. GUO Tong, Mr. WU Shuangsi and Ms. LIU Na.*